Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Márk Barok"'
Autor:
Jorma Isola, Marko Salmikangas, Márk Barok, Heikki Joensuu, Ana Martins, Vadim Le Joncour, Pirjo Laakkonen
Publikováno v:
Cancer Letters. 473:156-163
The majority of HER2-positive breast or gastric cancers treated with T-DM1 eventually show resistance to this agent. We compared the effects of T-DM1 and ARX788, a novel anti-HER2 antibody-drug conjugate, on cell growth and apoptosis in HER2-positive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7c0e451f0970c70a0b11763c5b668f7
https://doi.org/10.1016/j.canlet.2019.12.037
https://doi.org/10.1016/j.canlet.2019.12.037
Publikováno v:
Journal of Extracellular Vesicles, Vol 10, Iss 4, Pp n/a-n/a (2021)
Journal of Extracellular Vesicles
Journal of Extracellular Vesicles
Antibody‐drug conjugates (ADCs) are a new class of anti‐cancer drugs that consist of a monoclonal antibody, a highly potent small‐molecule cytotoxic drug, and a chemical linker between the two. ADCs can selectively deliver cytotoxic drugs to ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c62e2ee222b8f095020a933e4df038f
https://doi.org/10.1002/jev2.12070
https://doi.org/10.1002/jev2.12070
Publikováno v:
Applied Immunohistochemistry & Molecular Morphology. 26:212-219
Growth factor receptor HER3 (ErbB3) lacks standardized immunohistochemistry (IHC)-based methods for formalin-fixed paraffin-embedded (FFPE) tissue samples. We compared 4 different anti-HER3 antibodies to explain the differences found in the staining
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ade374067ac8921d880a0eb8d343f84
https://doi.org/10.1097/pai.0000000000000406
https://doi.org/10.1097/pai.0000000000000406
Autor:
Pirjo Laakkonen, Jorma Isola, Vadim Le Joncour, Ana Martins, Marko Salmikangas, Maija Puhka, Márk Barok, Heikki Joensuu
Publikováno v:
Molecular cancer therapeutics. 18(10)
Most patients with HER2-positive breast or gastric cancer exhibit primary or acquired resistance to trastuzumab emtansine (T-DM1), and such patients may have limited therapeutic options. XMT-1522 is a novel anti-HER2 antibody–drug conjugate. We com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9a3c3bbea79f3c4d20cec75c79f11c5
https://pubmed.ncbi.nlm.nih.gov/31292166
https://pubmed.ncbi.nlm.nih.gov/31292166
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-12 (2018)
BMC Cancer
BMC Cancer
Background Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that carries a cytotoxic drug (DM1) to HER2-positive cancer. The target of T-DM1 (HER2) is present also on cancer-derived exosomes. We hypothesized that exosome-bound T-DM1 may co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed2effd9ca84ce03e637d78d9c9bc949
https://doi.org/10.1186/s12885-018-4418-2
https://doi.org/10.1186/s12885-018-4418-2
Publikováno v:
Cancer Research. 78:756-756
Antibody-Drug Conjugates (ADC) represent a promising therapeutic modality for improving the clinical management of cancer. However, there now exists resistant mechanisms by cancer cells that are effective at ultimately reducing the cellular accumulat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32075a1d5d59b65a4a759dca053dcdc3
https://doi.org/10.1158/1538-7445.am2018-756
https://doi.org/10.1158/1538-7445.am2018-756
Autor:
Márk Barok
Publikováno v:
Hungarian Medical Journal. 2:317-328
Overexpression of ErbB2 (HER2), a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, occurs in 20–30% of invasive breast cancers and is associated with poor prognosis and rapid relapse. Since cancer cell grow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24abc290c83fe6b384b90a41e6b454c6
https://doi.org/10.1556/hmj.2.2008.2.18
https://doi.org/10.1556/hmj.2.2008.2.18
Autor:
János Szöllosi, Hideyuki Saya, Zsuzsanna Pályi-Krekk, Tamás Kovács, Péter Nagy, Osamu Nagano, Márk Barok
Publikováno v:
Cancer Letters. 263:231-242
Activation of the ErbB family of receptor tyrosine kinases is involved in a range of human cancers. Transmembrane signaling mediated by ErbB proteins is stimulated by peptide growth factors and is blocked by monoclonal antibodies such as trastuzumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44e3321f0ca57dc0be0883154ba5a1fd
https://doi.org/10.1016/j.canlet.2008.01.014
https://doi.org/10.1016/j.canlet.2008.01.014
Autor:
István Juhász, Eniko Toth, Márk Barok, Zsuzsa Rákosy, John W. Park, Péter Nagy, György Vereb, Margit Balázs, Jorma Isola, János Szöllosi, Andrea Treszl
Publikováno v:
Cancer Letters. 260:198-208
We have recently shown that despite of the fact that the ErbB2-positive JIMT-1 human breast cancer cells intrinsically resistant to trastuzumab in vitro, trastuzumab inhibited the outgrowth of early phase JIMT-1 xenografts in SCID mice via antibody-d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74f5f0b812cdb9a8e6e8602177ad4c5f
https://doi.org/10.1016/j.canlet.2007.10.043
https://doi.org/10.1016/j.canlet.2007.10.043
Autor:
Szilvia Ecsedi, Margit Balázs, Zoltán Szentirmay, Márk Barok, Ágnes Bégány, Laura Vízkeleti, Zsuzsa Rákosy, Zsuzsa Krekk, Zoltán Vokó, Mónika Gallai, Róza Ádány
Publikováno v:
International Journal of Cancer. 121:1729-1737
Copy number alterations of the epidermal growth factor receptor (EGFR) gene have been extensively analyzed in different cancers, but no data are available for primary malignant melanoma. The aim of the present study was to simultaneously investigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7176a0d39d983f2bd2b9074a1a02a25e
https://doi.org/10.1002/ijc.22928
https://doi.org/10.1002/ijc.22928